Utah Medical Products, Inc. — Q3 2013 Form 10-Q
Business context and period: UTMD manufactures and markets primarily single-use specialty medical devices. This unaudited report covers the quarter and nine months ended September 30, 2013; comparisons are with the corresponding 2012 periods. Unless noted, amounts are in thousands of dollars.
Financial performance
| Metric | Q3 2013 | Q3 2012 | 9M 2013 | 9M 2012 |
|---|---|---|---|---|
| Net sales | $10,032 | $10,489 | $30,408 | $31,719 |
| Gross profit | $5,949 | $6,477 | $18,279 | $19,286 |
| Operating income | $3,665 | $3,960 | $11,269 | $11,627 |
| Income before taxes | $3,577 | $3,849 | $10,991 | $11,215 |
| Net income | $2,571 | $2,721 | $7,938 | $7,910 |
| Diluted EPS | $0.68 | $0.73 | $2.11 | $2.13 |
| Gross margin | 59.3% | 61.7% | 60.1% | 60.8% |
| Operating margin | 36.5% | 37.8% | 37.1% | 36.7% |
| Net margin | 25.6% | 25.9% | 26.1% | 24.9% |
For the nine months, operating cash flow was $9,058, down from $10,499. Capital expenditures were $227; dividends paid were $1,824; and debt repayments were $2,909. Cash increased to $13,870 from $8,871 at year-end 2012. Working capital was $15,302, compared with $10,712.
At September 30, total notes payable were approximately $9,972, comprising $3,989 current and $5,983 long-term. Total liabilities were $23,523 and stockholders’ equity was $57,076. The company reported compliance with all loan financial covenants; existing notes were scheduled to be repaid by April 2016.
Changes and management’s explanation
- Q3 sales declined 4.4% and nine-month sales declined 4.1%. Management cited variable orders from major distributors, lower U.S. neonatal-device sales, and the stronger U.S. dollar. Sales to Cooper Surgical, the U.S. Filshie Clip distributor, fell $540 in Q3 and $673 for the nine months. Management said Q3 sales excluding Cooper and using prior-year exchange rates increased 2.4%.
- Gross margin fell, particularly in Q3, due to unfavorable product mix and currency effects, including a weaker Australian dollar. Nine-month operating margin improved despite lower sales, as operating expenses declined 8.5% to $7,009.
- Nine-month net income was approximately flat year over year: lower operating income was offset by a lower tax provision and reduced interest expense. The effective tax rate was 27.8%, versus 29.5% in 9M 2012. Diluted share counts increased, contributing to lower EPS.
- Cash generation supported debt reduction and dividends. Management attributed the increase in accrued expenses partly to a $916 quarterly dividend accrued at September 30 and paid afterward.
Outlook, risks, and notable items
Management said performance through the first nine months was generally consistent with its 2013 objectives: integrate multinational operations, develop additional gynecology products, maintain financial performance, use cash for debt reduction and shareholder returns, and consider suitable accretive acquisitions. No specific numerical earnings or revenue guidance was provided. Planned 2013 capital expenditures were expected to remain below depreciation.
The 2.3% U.S. medical device excise tax was in effect in 2013; it added $75 to Q3 and $220 to nine-month selling and marketing expense. Management cited regulatory burdens, healthcare reform, distributor dependence, hospital purchasing practices, product-liability exposure, foreign-exchange movements, competition, and remaining acquisition-related debt as risks. The company does not separately hedge currency exposure. It reported no litigation it believed could materially affect results, no material subsequent events, and no material changes to internal control over financial reporting. Disclosure controls were deemed effective.
Important facts for investors to verify
- Whether distributor ordering patterns, particularly Cooper’s, and U.S. neonatal sales recover or continue to pressure revenue.
- How product mix and AUD, GBP, and EUR movements affect sales and gross margins.
- The pace of debt repayment, covenant compliance, and the effect of interest rates on remaining borrowings.
- The sustainability of lower operating expenses and the reported tax-rate benefit, alongside the ongoing medical device excise tax.
- Whether cash generation can support dividends, product investment, and any acquisition while maintaining liquidity.